Enzon extends Series C Preferred exchange offer to Mar 9; rights plan extended to Mar 11

Viskase Holdings, Inc.

Exchange offer for Series C Preferred Stock extended to 11:59 p.m. ET on March 9, 2026.
Rights Agreement final expiration extended from March 2 to noon ET on March 11, 2026 via Eighth Amendment.
The offer, previously set to expire March 2, is part of the proposed merger with Viskase Companies, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Viskase Holdings, Inc. amended Eighth Amendment to the Section 382 Rights Agreement with Continental Stock Transfer & Trust Company (effective 2026-02-27).

Action: amendment
Counterparty: Continental Stock Transfer & Trust Company
Effective: 2026-02-27

Exact text from the filing

On February 27, 2026, Enzon Pharmaceuticals, Inc. (the “ Company ”) entered into the Eighth Amendment to the Section 382 Rights Agreement (the “ Eighth Amendment ”), which amends the Section 382 Rights Agreement, dated as of August 14, 2020 (the “ Rights Agreement ”), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent.

View on SEC.gov

314 material agreements filed in the last 30 days. Browse all material agreements →

Viskase Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-021051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.